Jev introduces fast, typed AI decisions, with early independent evidence for judging
TypeSafe AI released Jev on September 15, a specialized model that takes unstructured state and predefined questions and returns typed decisions with probabilities rather than generating prose. Vercel reported on September 18 that nearly 13% of its paid AI Gateway teams used Jev within its first 24 hours there; a September 22 independent preprint found Jev within three percentage points of its strongest LLM judge on preference and evidence-grounded factuality tasks at 0.36% of that judge's fee.
Why it made the cut: A model designed for low-latency classification, routing, and guardrail decisions could make a different class of AI-powered software practical, and both early platform use and an independent evaluation provide evidence beyond the launch claims. TypeSafe's larger speed and cost comparisons are self-run, Vercel's free introductory offer may have boosted early adoption, and the preprint reports larger gaps on tasks that require checking derivations or resisting elaborate wrong answers; none establishes general superiority or lasting production use.
↗
Official announcement and technical discussion · ↗
Early adoption data (Vercel) · ↗
Independent evaluation (preprint)
Five drugmakers show federated training can sharply improve AI protein–drug predictions without sharing raw data
AbbVie, Astex, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly fine-tuned OpenFold3 Preview 2 across 20,167 private protein–ligand structures while keeping every structure inside its owner’s environment. On 1,056 held-out structures, the resulting AISB-1-Fed model raised high-quality interface predictions from 35.6% to 52.1% and correct ligand poses from 28.9% to 46.8%, outperforming both the public OpenFold3 checkpoint and Boltz-2 on the consortium’s private evaluation.
Why it made the cut: The five-company experiment provides substantial evidence that otherwise siloed experimental structures can improve a shared drug-discovery model without pooling raw data. Announced September 14, it falls within this briefing’s 48-hour lookback. The evaluation uses held-out projects from the same participating companies, not a fully external test, and does not establish binding-affinity accuracy or general superiority across chemistry; the findings are consortium-reported, and the private data and trained weights are not public.
↗
Technical results and official announcement · ↗Consortium overview · ↗
OpenFold3 technical report · ↗
OpenFold3 code · ↗
Independent analysis (Nature)